| Molecular formula | C50H63N13O7 |
|---|
| Molecular weight | 958.1 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 10011122 |
|---|
What Alexamorelin Is
Alexamorelin is a peptide compound identified in chemical databases under PubChem CID 10011122, with a molecular formula of C50H63N13O7. It has no FDA-approved label, no approved brand name, and no established medical indication. It is classified here as an unapproved research compound, meaning any use outside of formal laboratory or clinical research settings falls outside recognized regulatory pathways.
Trial Footprint
There are currently no registered clinical trials for alexamorelin in the dataset reviewed. This absence of trial activity means there is no clinical-phase evidence available to describe its effects, safety profile, or potential uses in humans at this time.
FAQ
No. Alexamorelin has no FDA-approved label, no approved brand name, and no recognized medical indication. It is classified as an unapproved research compound.
Alexamorelin is a peptide compound with the molecular formula C50H63N13O7, listed in PubChem under CID 10011122. Beyond its chemical identity, no label or regulatory data is currently available.
No clinical trials for alexamorelin are currently registered in the dataset reviewed. This means there is no clinical evidence base describing its effects or safety in humans.
There is no adverse event reporting data available for alexamorelin at this time, so no side effect profile can be described.
Alexamorelin exists in chemical databases as a defined compound, but the absence of trials or a regulatory label means its research use has not been formally documented in the sources reviewed.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem
Updated 2026-09-19